Founded in 1979, Ajanta Pharma Limited emerges as a specialized pharmaceutical company that extends its quality medications to over 30 global destinations.
Deeply attuned to the needs of its clientele, the company employs advanced technology to craft innovative solutions that cater to distinct requirements.
Ajanta Pharma’s operational scope encompasses several domains: Branded Generics within India and Emerging Markets across Asia and Africa, Generics within the USA, and Institution Sales in Africa. This diversified approach renders their business model resilient and expandable.
Across its network of 7 cutting-edge manufacturing facilities stationed in India, Ajanta Pharma operates with precision. While 6 of these facilities focus on producing finished formulations, 1 facility concentrates on crafting Active Pharmaceutical Ingredients (APIs) primarily for internal consumption. Renowned for their superior quality, the company’s medications enjoy the trust of healthcare professionals and patients spanning over 30 nations.
Ajanta Pharma Ltd. Stock Quote #
- Open: ₹1,749.30
- High – Low: ₹1,757.00 – ₹1,733.35
- Previous Close: ₹1,749.25
- Total Traded Value: 47,451
- 52 Weeks High: ₹1,777.50 (Aug 03, 2023)
- 52 Weeks Low: ₹1,111.60 (Oct 28, 2022)
- Updated On: Aug 10, 2023 4:00 PM
Ajanta Pharma Buyback 2023 Detail #
| Issue Period | Mar 31, 2023 – Apr 10, 2023 |
| Security Name | Ajanta Pharma Limited |
| Issue Type | Tender Offer |
| Issue Size (Shares) | 2,210,500.00 |
| Issue Size (Amount) | ₹315.00 Crores |
| Buyback Price | ₹1425 per share |
| Face Value | ₹2 per share |
| Listing At | BSE, NSE |
Ajanta Pharma Buyback 2023 Issue Timetable #
| Last Date to buy shares | Mar 23, 2023 |
| Record Date | Mar 24, 2023 |
| Offer Opens On | Mar 31, 2023 |
| Last Date for receipt of Tender Forms | Apr 10, 2023 |
| Offer Closes On * | Apr 10, 2023 |
| Finalisation of Buyback Acceptance | Apr 13, 2023 |
| Last Date for settlment of bids | Apr 18, 2023 |
| Last Date for Extinguishment of Shares | Apr 27, 2023 |
Buyback Ratio #
| Category | Entitlement Ratio of Buyback | Shares Offered |
|---|---|---|
| Reserved Category for Small Shareholders | 20 Equity Shares out of every 99 Fully paid-up Equity Shares held on the Record Date. | 331,575.00 |
| General Category for all other Eligible Shareholders | 3 Equity Shares out of every 202 Fully paid-up Equity Shares held on the Record Date. | 1,878,925.00 |
Company Financials #
| Period Ended | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Mar-20 | 2,680.06 | 467.70 | |
| 31-Mar-21 | 3,778.72 | 2,915.67 | 653.87 |
| 31-Mar-22 | 4,055.58 | 3,456.67 | 712.68 |
| Amount in ₹ Crore | |||
Stock price at BSE (in preceding 3 months) #
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Feb-2023 | 1,252.00 | 4,523.00 | 1,197.49 |
| Jan-2023 | 1,222.90 | 3,168.00 | 1,186.12 |
| Dec-2022 | 1,272.00 | 1,192.00 | 1,210.90 |
Stock price at NSE (in preceding 3 months) #
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Feb-2023 | 1,254.00 | 1,151.35 | 1,198.12 |
| Jan-2023 | 1,224.00 | 1,150.00 | 1,186.49 |
| Dec-2022 | 1,266.25 | 1,150.25 | 1,210.19 |
Necessity of the Issue #
The buyback is being undertaken for the following reasons:
- The buyback will help the company to return surplus cash to its equity shareholders broadly in proportion to their shareholding, thereby enhancing the overall return to shareholders.
- The buyback consists of a reservation for the small shareholder. The company believes that this reservation for small shareholders would benefit a large number of public shareholders who would get classified as “small shareholders”.
- The buyback may help in improving return on equity, reduction in the equity base, thereby leading to a long-term increase in shareholders’ value.
- The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer.
- The buyback may lead to a reduction in outstanding Equity Shares, an improvement in earnings per equity share, and an enhanced return on equity.
Ajanta Pharma Buyback 2023 Documents #
Company Contact Information #
Ajanta House, Charkop,
Kandivali West,
Mumbai 400 067Phone: +91 22 6606 1000
Email: investorgrievance@ajantapharma.com
Website: http://www.ajantapharma.com/
Ajanta Pharma Buyback 2023 Registrar #
- Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083Phone: +91-22-4918 6270
Email: ajantapharma2023.buyback@linkintime.co.in
Website: https://linkintime.co.in/mipo/ipoallotment.html
Ajanta Pharma Buyback 2023 Manager #
Lead Manager(s)
- Edelweiss Financial Services Ltd
Registered Broker
- Nuvama Wealth Management Limited
Email: instops@nuvama.com
